Drugging the microbiome: targeting small microbiome molecules.

Area of Science:

• Microbiology
• Human Physiology
• Pharmacology

Background:

• The human microbiome, a diverse microbial community, influences host health and disease.
• Early research linked microbiome composition to disease associatively.
• Emerging evidence highlights microbiome metabolites as causal factors in disease phenotypes.

Purpose of the Study:

• To review notable microbial metabolites with therapeutic potential.
• To explore the concept of 'drugging the microbiome' for therapeutic benefit.
• To discuss the shift from associative to causal links between microbiome and disease.

Main Methods:

• Review of existing literature on microbial metabolites and their therapeutic promise.
• Analysis of traditional drug-development campaigns targeting microbiome-derived compounds.
• Exploration of enzymatic inhibitors for microbiome metabolite modulation.

Main Results:

• Identification of specific microbial metabolites with demonstrated therapeutic potential.
• Confirmation of causal roles for microbiome metabolic products in disease.
• Advancement of strategies for microbiome manipulation via live biotherapeutics and enzyme inhibitors.

Conclusions:

• Microbiome metabolites offer promising therapeutic targets.
• Modulating the microbiome presents a novel approach to disease treatment.
• Further research into microbiome-derived compounds is warranted for drug development.